Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.3252W HIGH $50.16
Volume
440.67 K
Value Traded
19.42 M
Short % Float
23.48%
-6.43%Week
-27.4%1 Month
+5.04%3 Month
+42.19%6 Month
+48%5 Year
+48%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.12 B
EPS (TTM)
-2.66
P/E Ratio
-
Ent. Value
788.70 M
Total Shares
32.26 M
Float Shares
23.92 M
Insiders
25.84%
Institutions
83.47%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
LBRX Catalyst Timeline
Dated clinical, regulatory and corporate events for LB Pharmaceuticals Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for LB Pharmaceuticals Inc
48Total events
15Upcoming
7Tier-1 (high impact)
2025 to 2029Coverage
Upcoming catalysts 2
Event history 30
▼Equity OfferingCorporate
Private placement of common stock and pre-funded warrants for $150 million gross proceeds
◆Management ChangeCorporate
Appointment of Christopher Zergebel as Senior Vice President, Clinical Operations
◆Oral PresentationPresentation
H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference presentation
▲Trial InitiationLB-102Trial
Initiated Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar depression
bipolar depressionsource ↗
▲PublicationLB-102Presentation
Published Phase 2 NOVA-1 results in JAMA Psychiatry
schizophreniasource ↗
▲PublicationLB-102Presentation
Publication of Phase 2 NOVA-1 trial results in JAMA Psychiatry
schizophreniasource ↗
◆Oral PresentationPresentation
Presentation at 25th Annual Needham Virtual Healthcare Conference
▲Oral PresentationLB-102Presentation
Oral presentation of post hoc analysis of LB-102 effect on cognitive performance at SIRS 2026
schizophreniasource ↗
▲Trial InitiationLB-102Trial
Initiation of Phase 2 ILLUMINATE-1 trial of LB-102 for bipolar depression
bipolar depressionsource ↗
▲Trial InitiationLB-102Trial
Initiation of Phase 2 ILLUMINATE-1 trial for LB-102 in bipolar depression
bipolar depressionsource ↗
▼Equity OfferingCorporate
Announced $100M private placement of common stock and pre-funded warrants
▲Trial InitiationLB-102Trial
Initiation of Phase 2 ILLUMINATE-1 trial in bipolar depression
bipolar depressionsource ↗
▲Primary Endpoint MetLB-102Clinical Data
Positive Phase 2 results for LB-102 in acute schizophrenia
acute schizophreniasource ↗
▲Topline ReadoutLB-102Clinical Data
Positive Phase 2 topline data for LB-102 in acute schizophrenia
acute schizophreniasource ↗
Past FDA Catalysts and PDUFA Decisions
How LBRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-10-13 | LB-102 | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$90M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 60%
Micro Cap(rank 395 of 658)
Percentile Rank
LB Pharmaceuticals Inc faces pipeline headwinds (33/100), with $224M risk-adjusted pipeline value, led by LB-102 in Bipolar I Disorder (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LB-102 Small moleculeNCT04588129 | Schizophrenia | Phase 3 | COMPLETED | 1,795 | Nov 15, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every LBRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LB-102 | schizophrenia | Phase 2 | 2026-10-06 | positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia.Read More | LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia TreatmentRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd.10% Owner | Buy | 286,205 664,649 held | $34.94 | 07/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LBRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 1.6 % (14.3 %) | 108.81 M | 3.35 M |
LBRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LBRX ranks across every disease it competes in
Competitive Position is a premium feature
See how LBRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLBRX News
LBRX▲ +1.3%today
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
LB Pharmaceuticals is set to host an R&D Day on October 27, 2026, focusing on LB-102, a novel treatment for schizophrenia. The event will feature expert presentations and discussions on the upcoming Phase 3 trial data. LB-102 has demonstrated significant efficacy in earlier trials and aims to address multiple neuropsychiatric disorders.
Read more →LBRXLB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
LB Pharmaceuticals has appointed Dr. Susan G. Kozauer as Chief Medical Officer. Dr. Kozauer brings over two decades of experience in neuropsychiatric drug development, having previously worked at Intra-Cellular Therapies. Her expertise will be crucial as the company prepares for the Phase 3 NOVA-2 trial of LB-102, an investigational medicine targeting underserved neuropsychiatric disorders.
Read more →LBRXLB Pharmaceuticals to Participate in Upcoming September Investor Events
LB Pharmaceuticals Inc. announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company aims to present its developments in neuromedicines, particularly its lead product candidate, LB-102, which targets neuropsychiatric disorders. The webcasts of these events will be available on their website.
Read more →LBRXLB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
LB Pharmaceuticals has appointed Joseph Miller as Chief Financial Officer, bringing over 20 years of biopharmaceutical finance experience. His expertise is expected to aid the company as it approaches significant clinical trial results for LB-102, a potential treatment for schizophrenia. The company aims to leverage Miller's background to enhance its growth and commercialization strategies.
Read more →LBRXLB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals reported its Q2 2026 financial results, highlighting an accelerated timeline for topline data from the Phase 3 NOVA-2 trial of LB-102 in schizophrenia, now expected in early 2027. The company also announced a $150 million private placement to fund pipeline expansion into new neuropsychiatric indications. Despite a significant net loss, the company maintains a strong cash position to support operations through 2029.
Read more →LBRX▲ +11.6%on this news· ran to +23% by day 3
LB Pharmaceuticals Announces $150 Million Private Placement
LB Pharmaceuticals has announced a $150 million private placement to fund the expansion of its pipeline, particularly for LB-102, aimed at treating neuropsychiatric disorders. The placement involves the sale of shares and warrants to institutional investors, with proceeds expected to support ongoing clinical trials and general corporate purposes. The private placement is set to close on July 30, 2026, pending customary conditions.
Read more →LBRX▲ +10.9%on this news
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals has accelerated the timeline for topline results from its Phase 3 NOVA-2 trial of LB-102 in schizophrenia, now expected in the first half of 2027. The trial's rapid enrollment reflects strong interest in the drug, which aims to address neuropsychiatric disorders. A pre-NDA meeting with the FDA is planned for the second half of 2027.
Read more →LBRXLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals has granted an inducement equity award to Christopher Zergebel, its new Senior VP of Clinical Operations, under Nasdaq Listing Rule 5635(c)(4). The award includes options to purchase 75,000 shares, vesting over four years. The company is advancing its lead candidate, LB-102, which has shown positive Phase 2 trial results for schizophrenia and is entering pivotal Phase 3 trials.
Read more →LBRXLB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
LB Pharmaceuticals has appointed Christopher Zergebel as Senior Vice President of Clinical Operations. With over 25 years of experience, Zergebel will lead efforts in executing multiple clinical trials for LB-102, a candidate aimed at treating schizophrenia and bipolar depression. The company is optimistic about the potential of LB-102 to meet significant patient needs.
Read more →LBRXLB Pharmaceuticals to Participate in Upcoming June 2026 Investor Events
LB Pharmaceuticals Inc. will participate in two upcoming investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The company aims to showcase its late-stage development of therapies for neuropsychiatric diseases, particularly its lead candidate, LB-102.
Read more →LBRXLB Pharmaceuticals to Participate in Upcoming June Investor Events
LB Pharmaceuticals Inc. has announced its participation in two upcoming investor conferences, the Jefferies Global Healthcare Conference on June 4, 2026, and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 16, 2026. The company is focused on developing innovative therapies for schizophrenia and other neuropsychiatric diseases, with its lead candidate, LB-102, showing promise as a potential first-in-class treatment.
Read more →LBRXLB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals reported its first quarter 2026 financial results, highlighting the initiation of two late-stage clinical trials for its lead product, LB-102, aimed at treating schizophrenia and bipolar depression. The company also announced a strong cash position expected to fund operations through multiple clinical milestones. Positive data from a prior Phase 2 trial has been published, supporting the drug's potential in neuropsychiatric disorders.
Read more →LBRXLB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals announced the publication of positive results from the Phase 2 NOVA-1 trial of LB-102 in JAMA Psychiatry. The investigational drug demonstrated significant efficacy in treating acute schizophrenia and is advancing to a pivotal Phase 3 trial (NOVA-2). If successful, LB-102 could be the first benzamide approved for schizophrenia in the U.S.
Read more →LBRX▼ -7.4%on this news
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
LB Pharmaceuticals Inc. announced that CEO Heather Turner will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. The company is focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders. Their lead candidate, LB-102, aims to be a first-in-class treatment for these conditions.
Read more →LBRXLB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
LB Pharmaceuticals presented new data on LB-102 at the SIRS conference, highlighting its potential to improve cognitive performance in schizophrenia patients. The Phase 2 NOVA-1 trial showed that LB-102 significantly enhances cognition independently of its effects on overall schizophrenia symptoms. The company is now evaluating cognitive performance as a secondary endpoint in its upcoming Phase 3 trial.
Read more →LBRXLB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
LB Pharmaceuticals presented new findings from the Phase 2 NOVA-1 trial of LB-102 at the SIRS Congress, highlighting its potential to improve cognitive performance in schizophrenia patients. The analysis showed that cognitive benefits were primarily a direct effect of LB-102, independent of overall symptom improvement. The company plans to evaluate cognitive performance as a secondary endpoint in its upcoming Phase 3 trial.
Read more →LBRXLB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
LB Pharmaceuticals reported positive results from its Phase 2 trial of LB-102 for schizophrenia and has advanced the drug into late-stage development with a pivotal Phase 3 trial. The company also plans to initiate a Phase 2 trial for major depressive disorder in 2027. With a strong financial position, LB Pharmaceuticals aims to expand its pipeline in neuropsychiatric disorders.
Read more →LBRXLB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
LB Pharmaceuticals has initiated its pivotal Phase 3 trial, NOVA-2, for LB-102, targeting schizophrenia. The trial aims to enroll around 460 patients and evaluate the drug's efficacy and safety, with results expected in the second half of 2027. If successful, LB-102 could become the first benzamide approved for schizophrenia in the U.S., addressing significant unmet needs in treatment.
Read more →LBRXLB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
LB Pharmaceuticals has appointed Dr. Robert Lenz to its Board of Directors, enhancing its leadership with his extensive experience in neuroscience R&D. The company is progressing its lead product candidate, LB-102, into late-stage clinical development for various neuropsychiatric disorders. Dr. Lenz expressed enthusiasm about contributing to the company's growth and advancing LB-102's potential therapeutic benefits.
Read more →About LB Pharmaceuticals Inc
Headquarters575 MADISON AVENUE, NEW YORK, NY, 10022
BIOPHARMAWATCH ELITE PLUS
Trade the next LBRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime